The Maharashtra Food and Drugs Administration (FDA) has ordered an immediate ban on the sale and distribution of Coldrif Syrup from Batch No. SR-13, following laboratory detection of a toxic contaminant and reports of child deaths in two states.
Sunday’s emergency alert comes after the cough syrup was found to contain Diethylene Glycol (DEG), a hazardous industrial substance known to cause severe kidney and liver damage, and potentially death, when ingested.
The regulatory action was prompted by tragic incidents in Madhya Pradesh and Rajasthan where children died after allegedly consuming the contaminated medication.
According to the FDA’s official statement, the affected batch was manufactured in May 2025 by Sresan Pharma, located in Tamil Nadu’s Kancheepuram district. The syrup, which contains active ingredients Phenylephrine Hydrochloride and Chlorpheniramine Maleate, carries an expiration date of April 2027.
State authorities have mandated all pharmacies, hospitals, and distributors to immediately cease selling or using the identified batch. The FDA has further instructed anyone in possession of the syrup to report it to local drug control authorities.
The administration has established multiple channels for public reporting, including toll-free helpline 1800-222-365, email address jchq.fda-mah@nic.in, and contact number 9892832289.
Maharashtra FDA officials are coordinating with drug regulators in Tamil Nadu to trace and contain the distribution of the contaminated batch. Retailers, wholesalers, and medical facilities have been directed to identify and quarantine any existing stocks.
FDA Drug Controller D.R. Gahane confirmed the department is implementing necessary precautions to prevent further incidents, urging public vigilance and cooperation from healthcare professionals to ensure complete market withdrawal of the dangerous product.
-
-
-
-
